BioTelemetry, Inc. Announces Retirement of Director Ronald A. Ahrens
September 24 2015 - 4:05PM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, announced today
that Board member Ronald A. Ahrens will retire after 7 years of
service to BioTelemetry shareholders.
Mr. Ahrens joined BioTelemetry’s Board in 2008 and has served as
Chairman of the Compensation Committee since 2009. Prior to
joining BioTelemetry, Mr. Ahrens had extensive experience as a
Director and Board consultant, most recently serving as Vice
Chairman of Temptime Corporation from 2004 to 2013 and as Chairman
of the Compensation Committee of VIASYS Healthcare Inc. from 2001
to 2007. Mr. Ahrens has over 40 years of management experience in
the healthcare industry, having held various leadership positions
with Merck & Co., including President of Merck Consumer
Healthcare Group Worldwide and Executive Vice President of Merck
Consumer Healthcare Group International. Mr. Ahrens
received an undergraduate degree from Concordia College and a
Masters in Sacred Theology from Concordia Seminary.
Joseph Capper, President and Chief Executive Officer of
BioTelemetry, Inc., commented, “We are extremely appreciative of
Mr. Ahrens’ service and contributions to our Company and our
shareholders. The management team of BioTelemetry, as well as his
fellow Board members, have benefitted greatly from his invaluable
insight and counsel throughout his tenure. The Company’s sustained
success over the past few years would not have happened without
Ron’s expertise and passion for our vision. We are enormously
grateful for his unwavering commitment and wish Ron a healthy,
happy and long retirement.”
About BioTelemetry, Inc.BioTelemetry, Inc.,
formerly known as CardioNet, Inc., is the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care. The Company
currently provides cardiac monitoring services, original equipment
manufacturing with a primary focus on cardiac monitoring devices
and centralized cardiac core laboratory services. More information
can be found at www.gobio.com.
BioTelemetry’s Cautionary Statement Regarding
Forward-Looking StatementsThis document includes certain
forward-looking statements within the meaning of the “Safe Harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as “expect,”
“anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises”
and other words and terms of similar meaning. Such forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties, including important factors that could
delay, divert, or change any of these expectations, and could cause
actual outcomes and results to differ materially from current
expectations. These factors include, among other things, our
ability to successfully integrate the Mednet, Biomedical Systems
and Radcore businesses into our business and the effect such
acquisitions will have on our results of operation, our ability to
successfully finalize a settlement of the Department of Justice
investigation, effectiveness of our cost savings initiatives,
relationships with our government and commercial payors, changes to
insurance coverage and reimbursement levels for our products, the
success of our sales and marketing initiatives, our ability to
attract and retain talented executive management and sales
personnel, our ability to identify acquisition candidates, acquire
them on attractive terms and integrate their operations into our
business, the commercialization of new products, market factors,
internal research and development initiatives, partnered research
and development initiatives, competitive product development,
changes in governmental regulations and legislation, the continued
consolidation of payors, acceptance of our new products and
services, patent protection, adverse regulatory action, and
litigation success. For further details and a discussion of
these and other risks and uncertainties, please see our public
filings with the Securities and Exchange Commission, including our
latest periodic reports on Form 10-K and 10-Q. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024